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Summary. Caspases are intracellular proteases that 
participate in apoptotic pathways in mammalian cells, 
including neurons. Here we review evidence that caspase 
inhibition, through pharmacological or molecular means, 
rnay inhibit neuronal cell death in a number of in vitro 
and in vivo models of neurological disease. It has 
recently become clear that, at least in most cell culture 
models,  caspase inhibition offers only transient 
protection, and that a caspase-independent death 
eventually occurs. This rnay be due to irreversible 
caspase-independent alterations at the leve1 of the 
mitochondria. Despite concerns that targeting caspases 
alone rnay prove insufficient to truly reverse the effects 
of various death stimuli, in vivo studies indicate that 
caspase inhibition promotes survival and functional 
outcome in a variety of neurological disease models. In 
addition, studies of human post-mortem material suggest 
that caspases are activated in certain human neurological 
diseases. Caspase inhibition rnay therefore provide a 
novel strategy for the treatment of such disorders. 
Caspas'es, through the generation of toxic fragments of 
critica1 protein substrates, rnay also be involved in 
earlier steps of neuronal dysfunction, such as protein 
aggregation in Huntington's and Alzheimer's disease, 
and therefore caspase inhibition rnay be of additional 
value in the treatment of these particular disorders. 
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Caspases within the apoptotic pathway 
Caspases are intracellular cysteine proteases that 
participate in apoptotic cell death pathways (Steller, 
1995; Fraser and Evan, 1996; Green and Kroemer, 1998; 
Green, 1998; Earnshaw et al., 1999). The foundations for 
current concepts of the biochemical and molecular 
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pathway of apoptosis were laid by the groundbreaking 
work of Horvitz and colleagues, who identified a 
number of genes that play a role in programmed cell 
death in the nematode C. elegans (Ellis and Horvitz, 
1986; Metzstein et al., 1998). Most notable amongst 
these were ced-3 and ced-4,  which promoted 
programmed cell death, and ced-9, which inhibited it 
(Avery and Horvitz, 1987; Yuan and Horvitz, 1990; 
Hengartner et al., 1992; Hengartner and Horvitz, 1994). 
Shortly thereafter Horvitz and colleagues discovered a 
homology between ced-3 and the mammalian gene 
encoding Interleukin 1-B converting enzyme (ICE), a 
cysteine protease involved in Interleukin 1-0 (IL1-B) 
processing (Yuan et al., 1993). Subsequently, a number 
of investigators cloned a large number of ICE 
homologues, which comprise the family of caspases 
(Fraser and Evan, 1996; Earnshaw et al., 1999). To date, 
14 members of the caspase family have been identified. 
They can be classified in various ways, depending for 
example on their substrate specificity, the presence or 
absence of a large prodomain, or their perceived position 
and role within the apoptotic pathway. Based on the 
latter, they are classified into ICE (caspase 1)-like 
caspases, which also play a role in inflammatory 
responses, caspase 3-like caspases, which are generally 
thought to be the final death effectors, and caspase 8-like 
caspases, which generally act as initiators or propagators 
of apoptot ic  s ignal ing (Earnshaw et  al., 1999).  
Mammalian homologues of ced-4, most notably Apaf-1, 
and of ced-9, comprising the bcl-2 family of proteins, 
have also been identified (Hengartner and Horvitz, 1994; 
Zhou et al., 1997; Adams and Cory, 1998). 
These genetic data, together with important work 
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via an apoptotic mechanism that is inhibited by 
treatment with the broad spectrum caspase inhibitor 
ZVAD-FMK or the caspase 3 like inhibitors DEVD- 
FMK or DEVD-CHO (Du et al., 1997; Dodel et al., 
1998). However, as has been observed with 6-OHDA, as 
the concentration of MPP+ increases, the mechanism of 
death shifts from one that is morphologically apoptotic 
and inhibitable by caspase inhibition, to one that does 
not manifest the morphological features of apoptosis and 
is not responsive to caspase inhibition (Choi et al., 
1999). 
The transplantation of embryonic dopaminergic 
tissue has been found to provide some functional benefit 
in certain patients. The major problem, however, is the 
significant loss of donor tiisue viability, mainly prior to 
and during the implantation p~ocedure. It has been 
estimated that less than 10% of the initial graft tissue 
survives and innervates the host striatum (Kordower et 
al., 1998), necessitating the use of a considerable amount 
of donor tissue. It has been shown that a proportion of 
the neurona1 loss in embryonic grafts is via apoptosis 
(e.g. Mahalik et al., 1994), indicating that 
neuroprotective anti-apoptotic agents might improve 
graft survival. Brundin and colleagues have shown that 
pre-treatment of dissociated embryonic nigral cell 
suspensions with the ICE-like caspase inhibitor YVAD- 
CMK significantly improved not only pre-implant 
survival, but also long term graft survival and 
innervation as evidenced by enhanced functional 
improvements in 6-OHDA lesioned animals (Schierle et 
al., 1999). These findings were extended with the 
observation that the caspase 3-like inhibitor DEVD- 
CMK, but surprisingly not the broad spectrum caspase 
inhibitor ZVAD-FMK, improved the survival of 
embryonic nigral grafts to over 30% (Hansson et al., 
2000). These data suggest that it may be possible to 
improve the success of fetal tissue transplantation, and 
reduce the substantial amount of donor tissue required, 
using caspase inhibition to increase graft tissue 
viability. 
Table 1. Summaiy of caspases found to be activated in animal models 
of human neurological disease. and the pharmacological and rnolecular 
inhibitors of caspase activation found to have neuroprotective effects. 
Results from mouse transgenic studies are indicated in italicized text 
(DN-1, overexpression of dominant negative caspase 1; XIAP, 
overexpression of X-chrornosome-linked inhibitor of apoptosis protein). 
CASPASE NEUROPROTECTION 
ACTlVATlON 
MPTPIG-OHDA 2.3 ZVAD, DN-1 
Hunt Overexpression 1 ZVAD, DN-1 
SOD1 Mutant 1 , 3  ZVAD, DN-1 
Focal/Global lschemia 1 , 3 , 8 , 9  WAD, DEVD, BAF, 
ZVAD, XIAP, DN-1 
BrainISpinal Cord Trama 1 , 3  ZVAD, YVAD, DEVD, 
DN- 1 
Animal models 
The animal models traditionally used to study PD 
employ injection of the neurotoxins MPTP (the parent 
compound of MPP+) or 6-OHDA, because these agents 
cause selective death of dopaminergic neurons of the 
substantia nigra, mimicking PD pathology. Animal 
models based on genetic defects in PD are gradually 
emerging. However, data on the mechanisms of cell 
death in these genetic models are not yet available. In 
accordance with the cell culture studies, 6-OHDA and 
MPTP administration may cause death that is primarily 
necrotic or apoptotic, depending on the exact regimen 
used and the developmental stage of the animal (for 
example, see Jackson-Lewis et al., 1995; Tatton and 
Kish, 1997 for an acute and chronic MPTP regimen 
causing respectively necrosis and apoptosis). 
Activation of caspase 3, using immuno- 
histochemistry with an antibody raised against the active 
p17 fragment of caspase 3, was shown in apoptotic and 
pre-apoptotic substantia nigra neurons following 6- 
OHDA injection in neonatal rats (Jeon et al., 1999). The 
antibody used for this study, designated CM1, and 
characterized by Srinivasan and co-workers (1998), does 
not react with the inactive proform of caspase 3 and thus 
is  a useful tool for the in situ identification and 
intracellular localization of activated caspase 3 (and 
perhaps caspase 7) in apoptotic cells. Another study, by 
Cutillas et al. (1999) showed that caspase inhibition with 
the general caspase inhibitor zVAD-FMK offered 
protection against 6-OHDA-induced neurodegeneration 
in adult rats. 
There is also evidence that MPTP-induced death 
involves caspases: Mice that received striatal injections 
of MPTP showed processing, indicative of activation, of 
caspase 2 (Yang et al., 1998), which was prevented by 
overexpression of the anti-apoptotic protein Bcl-2. In 
addition, transgenic mice expressing a dominant 
negative inhibitor of caspase 1 (DN 1) were resistant to 
chronic systemic MPTP-induced apoptosis of nigral 
dopaminergic neurons (Klevenyi et al., 1999). 
Human studíes 
As in the animal models, the examination of caspase 
involvement in PD is closely linked to the issue of 
whether apoptotic death occurs in the human disease. 
This is a controversia1 issue, with some groups providing 
Table 2. Summary of caspases found to be activated in acute and 
chronic human neurological disease. 
CASPASE ACTlVATlON 
Parkinson's Disease 3? 
Alzheimer's Disease 3 
Huntington's Disease 1 - 8  
Amyotrphic Lateral Sclerosis 1, 3-like 
Stroke 3 
BraidSpinal Cord Trauma 1,3  
Caspases in neurological disease 
evidence of apoptotic neuronal death (Mochizuki et al., 
1996; Anglade et al., 1997; Tompkins et al., 1997; Tatton 
et al., 1998) and others failing to report it (Banati et al., 
1998; Wullner et al., 1999). It seems apparent that 
methodological differences could account, at least in 
part, for the disagreement on this issue. This raises the 
question of the value of solely determining the 
mechanism of neuronal death, not just in PD but in other 
neurodegenerative diseases as well, based on the 
observation of nuclear apoptotic features without 
examining apoptosis-related biochemical changes within 
the tissue. Moreover, given that neurodegenerative 
diseases such as PD, AD, and HD progress over many 
years, examining post-mortem tissue, which represents 
the disease state at a s ingle point in time, for  
morphological evidence of apoptotic neuronal death is 
not likely to yield a large return. From a technical 
standpoint, reliance on a single biochemical measure to 
identify apoptotic neurons, such as  end-labeling 
fragmented DNA (e.g. TUNEL, or ISEL), may not be as 
reliable an indication as the combination of end-labeling 
with an examination of nuclear morphology (see Tatton 
et al., 1998 for discussion). 
Hartmann et al. (2000) utilized the CM1 antibody 
raised against the active conformation of caspase 3 to 
examine caspase 3 activation in post-mortem tissue from 
PD patients. Although the absolute numbers of 
neuromelanin containing neurons that were positive for 
active-caspase 3 was significantly lowered in PD tissue 
compared to age-matched controls, when the authors 
normalized this number to the estimated remaining 
dopaminergic neurons in the substantia nigra, the 
proportion was approximately 5-fold higher in PD brain. 
However, they were unable to detect processed caspase 3 
fragments by western blotting of substantia nigra lysates, 
which was likely due to the small numbers of positively 
stained neurons obsewed in tissue sections. In contrast, 
in a thorough screening of many apoptosis-related 
proteins in PD and diffuse Lewy body disease post- 
mortem tissue, Jellinger (2000) failed to detect evidence 
of activated capase 3 using the same active 
conformation-specific antibody (CM1). In this study, 
there were also no differences obsewed between PD and 
control tissue in the levels or distribution of other 
apoptosis-related proteins such as Bcl-2, Bax, Bcl-XL, 
or p53. Differences in tissue processing for 
immunostaining may account for the discrepancy 
between these studies. At this point, it is unclear whether 
caspase 3 is activated in PD substantia nigra. 
Alzheimer's disease (AD) 
Cell culture models 
The extracellular accumulation of 0-amyloid peptide 
( M )  is thought to lead to the neuronal loss associated 
with AD. The application of AB to cultured neuronal 
cells has accordingly been used as a cellular model of 
AD. Al3 has been shown to cause apoptotic cell death in 
these model systems (e.g. Loo et al., 1993), and to 
induce caspase activation (Ivins et al., 1999; Uetsuki et 
al., 1999; Giovanni et al., 2000; Selznick et al., 2000; 
Troy et al., 2000). In addition, pharmacological or 
molecular inhibition of particular members of the 
caspase family has been reported to offer partial or 
complete protection. In particular, caspases 2, 3, 8, and 
12 have been invoked (Ivins et al., 1999; Giovanni et al., 
2000; Nakagawa et a l . ,  2000; Troy et al. ,  2000). 
However, Selznick et al. (2000) reported that cortical 
neurons derived from caspase 3 knock-outs were not 
protected from AB-induced neuronal death. Differences 
in this respect, in particular with the study of Giovanni et 
al. (2000), who used the same experimental system, may 
be accounted for by different criteria used to assess death 
and/or different periods of observation. These data in 
conjunction suggest that multiple caspases may be 
involved in the apoptotic death of neurons exposed to 
AB. In most cases however it appears that caspase 
inhibition offers only transient protection, and non- 
apoptotic death eventually occurs (Giovanni et al., 2000; 
Selznick et al., 2000). 
AB is derived from y-secretase mediated processing 
of the amyloid precursor protein (APP). Emerging 
evidence suggests however that APP may also be 
cleaved by caspases at sites distinct from classic 
secretase processing. Caspases 3, 6 and 8 are able to 
cleave purified APP (Gewais et al., 1999; LeBlanc et al., 
1999; Pellegrini et al., 1999). Neurona1 cell lines 
induced to undergo apoptosis display cleavage of APP 
by caspase 3 or caspase 6, and such cleavage may 
increase the ultimate conversion of APP to Al3 (Gewais 
et al., 1999; LeBlanc et al., 1999). These results have 
raised the possibility of a dual role for caspases in 
neuronal death in AD. According to this hypothesis, low 
levels of caspase activity, which are insufficient to 
induce neuronal death, may processes APP, thus 
favoring the y-secretase-mediated production of the toxic 
AB fragment. AB deposits are subsequently formed, 
leading to initiation of the apoptotic pathway, 
culminating in caspase activation. This scenario is 
rendered more likely by the recent discovery that even 
caspase proforms can have low levels of enzymatic 
activity (Yang et al., 1998; Kumar, 1999). 
Animal models 
There is no convincing report of caspase activation 
in animal models of AD. This may in part be due to the 
paucity of neuronal cell death observed in the most 
commomly used model, the overexpression of mutated 
APP. Selznick et al. (1999), using the CM1 antibody, did 
not detect activated caspase 3 in such animals, which 
already had evidence of marked amyloid deposition and 
behavioral deficits. 
Human studies 
In studies of AD post-mortem tissue, Stadelmann et 
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al. (1999) and Selznick et al. (1999) observed CM1- 
positive immunoreactivity in hippocampal neurons. The 
CM1 labeling occurred in neurons with apoptotic 
nuclear features such as condensed and fragmented 
nuclei and in neurons with evidence of granulovacuolar 
degeneration. However, no specific CM1 labeling was 
obsewed within neurons associated with senile plaques 
or neurofibrillary tangles. This contrasts with studies in 
which caspase-cleaved actin, termed fractin, or a 
caspase-cleaved fragment of APP were localized with 
specific antibodies in areas with senile plaques in AD 
hippocampus (Yang et al., 1998; Gervais et al., 1999). 
The rod-like inclusions found in processes of 
hippocampal CA1 neurons (Hirano bodies) also stained 
with the fractin antibody. The fractin positive neurons, 
however, did not co-localize with activated caspase 
3/CM1 staining (Rossiter et al., 2000). Taken together, 
these results suggest that there is probably limited 
caspase 3 activation in AD brains, perhaps restricted to 
the hippocampus. It is possible that the more widespread 
evidence of caspase-cleaved fragments within areas of 
amyloid deposition reflects cleavage by other caspases. 
Huntington's disease (HD) 
Cell culture studies 
In a similar fashion to AD, a self-amplification 
cascade of caspase activation has been proposed for 
neuronal toxicity in polyglutamine disorders such as HD 
(Wellington and Hayden, 2000). Caspases, most 
prominently caspase 3, have been shown to cleave the 
wild type or mutant huntingtin protein, generating 
truncated fragments. Such truncated fragments 
containing expanded polyglutamine repeats have shown 
increased toxicity and propensity to aggregate compared 
to the full length protein, and may also influence the 
intracellular localization of aggregates (Goldberg et al., 
1996; Lunkes and Mandel, 1998; Martindale et al., 1998; 
Wellington et al., 1998). Wellington et al. (2000) 
mutated the predicted caspase 3 cleavage site on the 
huntingtin protein. This resulted in reduced toxicity and 
aggregate formation, demonstrating a role for caspase- 
mediated cleavage of huntingtin in inclusion formation 
and death, at least within this cellular context. 
Another site of potential caspase involvement in the 
pathogenesis if HD was suggested by Sanchez et al. 
(1999). These authors showed that caspase 8 was 
recruited to intracellular aggregates, most likely via its 
adaptor FADD, and subsequently activated, in neuronal 
cells expressing an expanded polyglutamine repeat. 
Caspase inhibition prevented death, but not inclusion 
formation. Similarly, Saudou et al. (1998), using the 
caspase 3-like inhibitor DEVD-CHO, prevented death, 
but not inclusion formation, in cultured striatal neurons 
expressing truncated forms of huntingtin with expanded 
polyglutamine repeats. In contrast, Kim et al. (1999), 
using immortalized striatal cells expressing truncated 
mutant forms of huntingtin, found that the caspase 3-like 
inhibitor DEVD-FMK inhibited inclusion formation, but 
not death. The general caspase inhibitor zVAD-FMK 
prevented death, but not inclusions. The requirement of 
caspase activation for polyglutamine induced neuronal 
death was questioned by Moulder and co-workers (1999) 
where it was reported that caspase inhibition only 
slightly delayed rather than prevented neuronal death 
induced by a polyglutamine-GFP fusion protein. The 
discrepancies in these studies may be accounted for, at 
least in part, by differences in the cellular systems and 
forms of polyglutamine proteins used. 
Taken together, these data suggest a scenario for HD 
(that is applicable to most other polyglutamine disorders 
as well, for example see Ellerby et al., 1999) in which 
mutant huntingtin is cleaved by low levels of caspase 
activity insufficient to kill the cell. This cleavage 
generates fragments that form aggregates and enhance 
susceptibility to apoptotic stimuli. Caspase-cleaved 
fragments may be further cleaved and thus enter the 
nucleus, which may be a critica1 event in the triggering 
of the death of the cell (Saudou et al., 1998). Aggregates 
may serve as the nidus for the recruitment and activation 
of caspases, as suggested by Sanchez et al. (1999). This 
would lead to an amplification cascade, in which further 
caspases are activated, leading to further huntingtin 
cleavage, aggregation and eventually death of the cell. 
Thus, caspases may be involved at multiple steps in this 
process. It is possible that different caspases are 
pieferentially activated at each leve1 (Wellington and 
Hayden, 2000). 
Animal models 
Transgenic mice (designated R6/2) that overexpress 
a fragment of human huntingtin protein with an extended 
polyglutamine region show reduced survival, neuronal 
aggregates, and behavioral deficits similar to HD 
(Mangiarini et al., 1996). In human HD cases there is 
widespread neuronal loss throughout the caudate, 
putamen and frontal lobes; however, in this mouse 
model, there have been conflicting reports concerning 
the presence of neuronal death and whether this death is 
apoptotic (Reddy et al., 1998; but see also Turmaine et 
al., 2000 for evidence of non-apoptotic neuronal loss in 
R6/2 HD mouse). In another recently described 
transgenic model, full-length mutant hutntingtin is 
expressed under the control of its natural promoter. In 
this mouse, intranuclear aggregates of N-terminal 
huntingtin are seen as well as evidence of neuronal 
degeneration with some features of apoptotic death, such 
as condensation and marginization of chromatin, 
particularly in the lateral regions of the striatum 
(Hodgson et al., 1999). 
Ona and colleagues (1999) recently showed 
evidence of caspase 1 (ICE) activity in the brains of the 
R6/2 mice. In addition, in double transgenic mice that 
also express a dominant negative inhibitor of ICE, 
disease onset and the formation of neuronal inclusions 
was significantly delayed, and survival was extended. 
Caspases in neurological disease 
Single transgenic mice expressing only the mutant 
huntingtin protein that were treated with a general 
caspase inhibitor showed similar improvements (Ona et 
al. ,  1999). Other evidence of the involvement of 
caspases from animal models of HD is provided by the 
observation that caspases 1 and 3 are upregulated at the 
level of mRNA in the R6/2 HD transgenic mouse (Chen 
et al., 2000). The differences in neuropathological 
outcomes in the different transgenic models currently 
available make interpretation of the evidence concerning 
caspase activation difficult ,  particularly for  the 
placement of caspase activation within the context of 
disease progression (Le. cleavage of mutant or wild type 
huntingtin andlor downstream pro-apoptotic effects). 
Human studies 
Extending their studies from the cell culture and 
animal models of the disease, Ona et al. (1999) and 
Sanchez et al. (1999) have shown evidence for activation 
of caspase 1 and caspase 8 in HD brains. Activation of 
caspase 1 was ascertained through activation of its 
substrate, IL-18. It is unclear however whether the 
activation of caspase 1 occurred within neurons. It is 
possible that the increase in IL-1B reflects instead an 
inflammatory reaction from microglial cells. Sanchez et 
al. (1999) showed that activated caspase 8 was present 
within insoluble fractions of HD brains, further 
supporting the idea that caspase 8 is recruited to 
aggregates and is subsequently activated. 
Amyotrophic Lateral Sclerosis (ALS) 
Cell Culture Studies 
Mutant Superoxide Dismutase 1 (mSOD1) is  
responsible for a proportion of familia1 ALS cases, 
possibly through the triggering of oxidative stress. 
Overexpression of mSODl has accordingly been used in 
both cell culture and animal models of ALS. Ghadge et 
al. (1997), using neurona1 PC12 cells, showed protection 
from mSODl expression-mediated apoptotic death with 
treatment with the general caspaSe inhibitor zVAD-FMK 
or the more specific ICE inhibitor YVAD-CMK. 
Pasinelli et al. (1998) showed activation of ICE in 
neuroblastoma cell lines expressing mSOD1. Inhibition 
of ICE-like caspases was partially effective in protecting 
these cells when they were exposed to oxidative stress. 
Using a different strategy, Troy et al. (1996) induced 
apoptotic death of PC12 cells and sympathetic neurons 
by inhibiting endogenous SOD1. They found that 
inhibitors with relative specificity for ICE were 
, 
protective and that IL-1B was activated. In conjunction, 
these data suggest involvement of at least caspase 1 
(ICE) in cell culture models of ALS. 
Animal models 
Severa1 studies now indicate that transgenic mice 
overexpressing mSODl also show evidence of caspase 
activation. Pasinelli et al. (1998), Li et al. (2000b), and 
Vukosavic et al. (2000) have shown processing and 
activation of caspase 1 in spinal cord lysates from such 
transgenic ALS mice. Spooren and Hengerer (2000), Li 
et al. (2000b) and Vukosavic et al. (2000) have also 
shown activation of caspase 3, by demonstrating positive 
CM1 staining, caspase 3 processing and caspase 3-like 
enzymatic activity. In one of these studies, it was shown 
that caspase 3 was activated subsequent to caspase 1 
(Vukosavic et al., 2000). In view of these findings, Li et 
al. (2000b) suggested that early caspase 1 activation may 
lead to the processing and release of IL-1B which may 
act as a diffusible pro-apoptotic signaling molecule (see 
Troy et al., 1996; Fink et al., 1999). However, at this 
point it is not known whether caspase 1 is situated 
directly upstream of caspase 3. Activation of both 
caspases was significantly delayed in double transgenic 
mice that also overexpress the anti-apoptotic protein 
Bcl-2 (Vukosavic et al., 2000), suggesting that the 
previously reported beneficial effects of Bcl-2 in this 
model occur upstream of the caspases, likely at the level 
of the mitochondria (Kostic et al., 1997; Vukosavic et 
al., 1999). There is also evidence that caspase inhibition 
protects against mSOD1-induced motor neuron death. 
Age of onset of the disease was delayed, mortality was 
improved and behavioral benefits were observed in mice 
treated with a general caspase inhibitor (Li et al., 
2000a,b). Double transgenics overexpressing, in addition 
to mSOD1, a dominant negative inhibitor of caspase 1 
(DN 1) showed similar beneficial effects (Friedlander et 
al., 1997). Recently, it has also been reported that 
cytochrome c is  released from mitochondria in 
asymptomatic transgenic mice expressing mutant SOD1, 
suggesting propagation of an apoptotic death pathway 
(Guegan et al., 2000). Additionally, double transgenic 
mice also expressing a dominant negative inhibitor of 
caspase 1 showed attenuated release of cytochrome c. 
Taken together these data suggest that a) there exists an 
early activation of caspases upstream of mitochondria in 
the spinal cord of transgensic ALS mice, and b) i t  is 
possible that an early inflammatory reaction may occur 
(e.g. the processing of IL-1B) that initiates an apoptotic 
pathway and that the beneficial effects of caspase 
inhibition, particularly of caspase 1, may be due to the 
disruption of this response rather than of downstream 
effector caspase activity. 
Human studies 
Taken together these data from cell culture and 
animal studies suggest that caspases may be relevant to 
motor neuron death in ALS. Importantly, caspase 
inhibition appears to significantly delay the disease 
process in these models. A study of pathological 
material from human ALS cases further supports caspase 
involvement. Martin (1999) detected cleavage of DNA 
fragmentation factor-40 (DFF-40), a substrate of caspase 
3, in both motor cortex and in spinal cord anterior horn 
Caspases in neurological disease 
compared to normal controls, suggestive of caspase 3 
activity. Evidence of caspase 3 activity was further 
provided by cleavage of labeled caspase 3-like 
pseudosubstrate by lysates from motor cortex, but not 
anterior horn. The lack of caspase 3 like activity detected 
in the anterior horn is surprising given the high levels of 
cleaved DFF-40 in this region; however this may have 
been related to the sampling technique employed by the 
author (tissue micropunches rather than dissected 
anterior horn; Martin, 1999). An increase of IL-1B in 
spinal cord of ALS patients was also reported by Li et al. 
(2000b), suggesting caspase 1 activation. As in HD, it is 
unclear whether this activation occurs within neurons, 
and whether it is related to apoptosis or to an 
inflammatory response. 
Animal models 
The involvement of caspases in the neuronal damage 
caused by stroke has been demonstrated in severa1 
systems using different models of ischemia. For 
example, cleavage of fluorogenic caspase 3-like 
subtrates has been detected in brain homogenates 
following brief middle cerebral artery (MCA) occlusion 
(Chen et al., 1998; Fink et al., 1998); however the 
increase was not detected until approximately 9 hr 
following restoration of normoxia. Additionally 
processed fragments of the pro-form of caspase 3 were 
detected using western blotting. Moreover, infarct 
volume and caspase cleavage were reduced by treatment 
with a preferential caspase 3 like inhibitor. Molecular 
inhibition of caspase 3 has also been shown to reduce 
neuronal death and improve behavioral recovery in 
transient forebrain ischemia (Xu et al., 1999). This 
inhibition was induced by overexpression of X- 
chromosome linked inhibitor of apoptosis protein 
(XIAP), and confirmed by the reduction in appearance 
of immunoreactivity to the active ~ 1 7 1 1 2  subunit of 
caspase 3 in transgenic mice. Conversely, while the 
caspase 3 like inhibitor DEVD-FMK was able to reduce 
the delayed neuronal death in the hippocampus and 
inhibit caspase 3 like activity, it did not prevent the 
deficits in long term potentiation in the CA1 region of 
the hippocampus following transient forebrain ischemia 
(Gillardon et al., 1999). 
Evidence of caspase 1 like activation has also been 
reported in animal models of stroke. Transient MCA 
occlusion led to increased levels of IL-1B in cerebral 
tissue indicative of processing by ICE like caspases 
(Hara et al., 1997) which was inhibited, along with 
infarct size, by ICV administration of a broad spectrum 
caspase inhibitor ZVAD-FMK. Similar reductions in 
infarct size have also been seen in cortex and striatum by 
ICV administration of ZVAD-DBC 24 hr following 
transient focal ischemia (Loddick e t  al. ,  1996). 
Moreover, functional recovery was also observed in 
animals treated with ZVAD-FMK, the caspase 3 like 
inhibitor DEVD-FMK or the caspase 1 like inhibitor 
YVAD-FMK, showing that caspase inhibition can not 
only ameliorate pathological changes associated with 
ischemic insults but also behavioral deficits.  
Additionally, transgenic mice expressing a dominant 
negative caspase 1 inhibitor, which show impaired 
processing of IL-lB, are also resistant to neuronal 
damage induced by focal ischemia (Friedlander et al., 
1997) and show reduced neurological deficits compared 
to control animals. 
In a model of transient spinal cord ischemia, the 
involvement of the Fas-caspase 8 death pathway was 
implicated (Matsushita et al., 2000). The active p18 
subunit of caspase 8 was detected in neurons within the 
intermediate and ventral horn of ischemic spinal cord as 
early as 90  min following re-perfusion, followed 
temporally by activation of caspase 3. Additionally, Fas 
expression was found to increase within the same 
population of neurons, and evidence of the formation of 
Fas-caspase 8 death receptor complexes, using co- 
immunoprecipitation from spinal cord lysates, was 
reported. This sequential activation of caspase 8 
followed by caspase 3 was also reported by Velier and 
co-workers (1999) using a panel of novel antibodies 
recognizing the active conformations of caspase 3 and 8 
both in situ and in brain lysates. In a canine model of 
global ischemia, caspase 9, of which a proportion 
normally is located within the intermembrane space of 
mitochondria (e.g. Susin et al., 1999), translocates from 
the mitochondria to cytosolic and nuclear compartments 
(Krawejski et al., 1999) in neurons that appear pre- 
apoptotic. 
Considerable evidence exists pointing to the 
involvement of IL-1B maturation in post-ischemic 
damage (see Touzani et al., 1999 for review). As 
outlined above, processing of IL-1B occurs relatively 
early, and it is thought that of the cysteine proteases 
currently known, only caspase 1 is capable of processing 
this cytokine (Talanian et al., 1997). Inhibition of 
caspase 1,  either with pharmacological agents or by 
expressing dominant negative inhibitors, and the 
subsequent attenuation of IL-1B maturation may be the 
critica1 target for abbrogation of ischemic damage. In 
support of this idea, IL-1B receptor antagonists have 
provided neuroprotection in models of ichemia and 
oxidative stress (e.g. Troy et al., 1996), thus indicating 
that activated IL-1B may initiate apoptotic pathways in 
neuronal cells. Animal studies of caspase activation in 
stroke point to severa1 pathways involving different 
caspases. Additionally, the Fas-caspase 8 pathway and 
the subsequent activation of caspase 3 has been shown to 
play a role in the delayed neuronal death occurring 
following ischemic insults. However to our knowledge, 
the temporal relationship between caspase 1 mediated 
processing of IL-1B and activation of the caspase 8 
pathway has not yet been examined. 
Human studies 
It is now believed that apoptosis contributes to the 
loss of neurons during the post-ischemic period in a 
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wave of delayed neuronal death (see Choi, 1996; 
Charriaut-Marlangue et al., 1998 for review). Activation 
of caspase 3 has been observed in human brain 
following transient global ischemia (cardiac arrest), 
using immunoreactivity with the CM1 antibody (Love et 
al., 2000a),  and elevated levels  of caspase 3 
immunoreactivity, using a non-specific antibody that 
recognizes both the active and pro-forms, has also been 
reported along with DNA fragmentation indicative of 
apoptotic neuronal death (Love et al., 2000b). 
Trauma 
Animal studies 
A s  in ischemic insults, evidence exists that a 
significant loss of neurons, via an apoptotic mechanism, 
occurs during the period following the initial traurnatic 
injury in both brain and spinal cord. Reproducible 
animal models are available to examine the biochemical 
pathways that mediate this death. 
In the rodent model of spinal cord injury, there is 
evidence of both caspase 1 (Li et al., 2000a,b) and 
caspase 3 activation (Springer et al., 1999; Li et al., 
2000a). Increased levels of mature IL-IR, indicative of 
caspase 1 activity, in addition to the appearance of 
processed active subunits of both caspase 1 and caspase 
3 in spinal cord lysates, were seen (Li et al., 2000a). 
Localized application of the broad spectrum caspase 
inhibitor ZVAD.fmk or overexpression of a dominant 
negative caspase 1, significantly reduced not only 
apoptotic neuronal death and caspase 1 and 3 activity, 
but also significantly increased behavioral recovery. Of 
particular note was that caspase inhibition, either 
pharmacological or molecular, while ongoing since the 
initial  injury, did not prevent early functional 
deterioration, but started showing a beneficia] functional 
effect 5 days following injury (Li et al., 2000a). This 
suggests that caspase inhibition specifically targeted 
neurological deficits due to delayed neuronal (and non- 
neuronal) apoptotic death rather than the initial insult. 
Similar techniques are utilized to model trauma that 
occurs to the brain as are used in spinal cord injury 
models. Here, there is also evidence of activation of 
caspase 1, from increased levels of processed IL-113 
(Fink et al., 1999), and of caspase 3, from detection of 
enzymatic activity and of cleavage of the caspase 3 
target proteins DNA-dependent protein kinase and 
inhibitor caspase-activated deoxyribonuclease (Clark et 
al., 2000). Additionally, neuroprotection and a reduction 
in caspase activation was observed in animals that were 
pretreated or  simultaneously treated with the broad 
spectrum caspase inhibitor ZVAD.fmk or the caspase 1 
like inhibitor YVAD.fmk (Fink et al., 1999), and the 
caspase 3 like inhibitor DEVD.fmk (Clark et al., 2000). 
Transgenic animals that overexpressed the dominant 
negative caspase 1 gene were also protected against 
brain trauma and showed amelioration of functional 
deficits (Fink et al., 1999). However, while inhibition of 
caspase 3 like caspases had a significant effect on 
neuronal loss and biochemical changes following brain 
injury, there was no impact on functional recovery seen 
(Clark et al., 2000). In this model, an additional insult of 
brief hypoxemia was imposed which may have obscured 
any functional improvements afforded by caspase 
inhibition. It is also possible that in brain injury, 
inhibition of caspase 1, but not 3, may offer functional 
benefits, if the latter lies too far downstream in the cell 
death pathway. As in ischemic injury, it is possible that 
the critica1 point for intervention may be the caspase 1 
mediated processing of IL-ID, which may lie upstream 
of initiation of a pro-apoptotic signaling cascade. 
However, a careful exmamination of the time course of 
IL-113 maturation with respect to the activation of 
downstream caspases is still lacking. 
Human studies 
There is limited data available concerning the 
activation of caspases following traumatic brain or 
spinal cord injury in humans. However, evidence of both 
apoptot ic  neuronal and non-neurona1 death and 
activation of caspase 3, using the active conformation- 
specific antibody CM1, has recently been reported in 
post-mortem tissue examined from human spinal cord 
injury patients (Emery et al., 1998). Additionally, tissue 
samples obtained from traumatic brain injury patients 
during surgical decompression procedures, revealed 
evidence of both apoptotic neuronal death and activation 
of caspase 1 and caspase 3, by the detection of the 
processed active subunits (Clark et al., 1999). 
Piifalls 
Despite compelling evidence that caspases are 
involved in neuronal cell death pathways that are 
relevant to neurological disease states, there are a 
number of pitfalls that need to be taken into account 
before one enthusiastically subscribes to the notion of 
administering caspase inhibitors for al1 neurological 
diseases  in which cell  death plays a role.  These 
reservations are based on theoretical concerns, but also 
on some experimental data, mostly from neuronal cell 
culture experiments. 
Although initially it appeared that caspase inhibition 
provided a prolonged protection from cell death in a 
variety of neuronal cell culture systems, it gradually 
became apparent that this protection was only transient. 
For example, DNA-damaged embryonic cortical neurons 
are protected from death for 12  hr through the use of 
general caspase inhibitors, but undergo a delayed cell 
death at 24-48 hrs (Stefanis et al., 1999). NGF-deprived 
sympathetic neurons are protected from death via 
caspase inhibition for 48-72 hrs, but they also die later 
on (Deshmukh et al., 2000). Similar observations have 
been made, as we already mentioned, in the models of 
AB- and polyglutamine-induced death (Moulder et al., 
1999;  Giovanni e t  al., 2000). Why does caspase 
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inhibition in post-mitotic neurons provide only transient 
respite from death? We and others have proposed that 
this is due to the fact that caspase involvement lies 
downstream of the mitochondrial checkpoint (Green, 
1998; Stefanis et al., 1999; Deshmukh et al., 2000). 
Indeed, inhibiting caspases does not prevent cytochrome 
c release from the mitochondria (Green, 1998; Neame at 
al., 1998; Stefanis et al., 1999; Deshmukh et al., 2000). 
Cytochrome c loss from the mitochondria would be 
expected to lead to dysfunction of the respiratory chain 
and energy depletion. This notion is supported by the 
fact that the mitochondria in the caspase inhibitor-treated 
cultures gradually lose their transmebrane potential, at 
the same time that they become committed to the 
delayed death (Stefanis et al., 1999; Deshmukh et al., 
2000). Loss of mitochondrial function and transmebrane 
potential could lead to death through energy depletion or 
through other mechanisms, such as release of reactive 
oxygen species or calcium from the dysfunctioning 
mitochondria. Interestingly, a recent report suggests that 
the commitment point ta  death of NGF-deprived 
sympathetic neurons may depend on their functional 
state, and in particular on the presence or absence of 
axons. Axotomized BAF-treated neurons show no  
sustained survival compared to untreated neurons and, 
remarkably, eventually show depletion of mitochondria, 
despite preservation of the other intracellular organelles 
(Fletcher et al., 2000). These findings further support the 
idea that mitochondrial dysfunction may be a limiting 
factor for caspase-targeted therapies, at least in certain 
settings. Apart from cytochrome c, other apoptogenic 
factors may be released from the mitochondria,  
independent of caspase inhibition. One such factor is 
Apoptosis Inducing Factor (AIF), which translocates to 
the nucleus and causes cell death even in the presence of 
caspase inhibition (reviewed by Daugas et al., 2000). 
Other mechanisms have also been postulated to account 
for the transient effects of caspase inhibition on neuronal 
survival. For example, another type of cell death, 
autophagy, in which the cell creates double membrane 
structures that engulf and ultimately digest intracellular 
organelles, has been linked to the death that occurs in the 
presence of caspase inhibition (Xue et al., 1999). 
Another issue, that is linked to the above, is the 
functional status of the neurons that survive through 
caspase inhibition. Neurons, for example the BAF- 
treated NGF-deprived sympathetic neurons, which are 
transiently protected from death, show decrease of cell 
size and metabolic rate. Never the less, these neurons, 
when treated again with NGF, rapidly increase their 
metabolic rate and enlarge (Deshmukh et al., 1996). 
These neurons are also able  to repopulate their 
mitochondria with cytochrome c (Martinou et al., 1999; 
Fletcher et al., 2000). The caspase inhibitor-saved 
neurons aslo show neurophysiological alterations, which 
are reversible with reinstatement of NGF treatment 
(Werth et al., 2000). These data in conjunction indicate 
that the caspase inhibitor-saved neurons are functional, 
but at a lower leve1 compared to healthy neurons. 
Caspase inhibition in this setting serves to buy time for 
the neurons, until a more drastic intervention, in this 
case readdition of trophic factor, truly reverses the 
effects of the death stimulus. 
There is also evidence that the dependence on 
caspases decl ines  with neuronal maturation. 
Pharmacological caspase inhibition delays the death of 
DNA-damaged embryonic cortical neurons, but not of 
neurons derived from post-natal cultures (Johnson et al., 
1999a,b). In addition, whereas cortical neurons derived 
from E16 caspase 3 knock-out mice are partially 
protected from DNA damage-induced death, neurons 
derived from E19 embryos are not (Keramaris et al., 
2000). Caspase inhibition may therefore be more 
effective in preventing death induced at earlier 
developmental stages. This raises concerns about the use 
of caspase inhibitors in neurodegenerative diseases or 
stroke, which predominantly occur in older adults. 
A theoretical concern that arises with the use of 
caspase inhibitors and other anti-apoptotic strategies is 
that normal cell turnover that occurs throughout life may 
be adversely affected by apoptosis inhibition. Another 
theoretical concern is that inhibiting apoptosis may lead 
to enhanced tumorigenesis. In addition, caspases may 
play other roles in the cells apart from mediating cell 
death. In this case, inhibiting caspases, especially long- 
term, may lead to disruption of cell  homeostasis. 
However, no such role has been identified up ti11 now, 
except  for  a role for  caspase 1-like caspases in 
inflammatory responses. Such concerns,  albeit  
theoretical, may have an impact on the design of caspase 
inhibitors. It appears that distinct members of the 
caspase family may be involved in neuronal death, 
depending on the initiating stimulus and the cell type 
(Troy et al., 1997; Park et al., 1998). One could envision 
therefore therapeutic strategies targeted against specific 
members of the caspase family, depending on the insult 
and the affected neuronal population. Thus, a more 
general inhibition of caspases and apoptotic pathways 
could be avoided. 
Conclusion 
In conclusion,  there i s  substant ial  evidence 
indicating that caspase inhibition may provide 
neuroprotective effects for a variety of neurological 
diseases. Recent animal studies in particular suggest that 
caspase inhibition significantly delays death and 
neurological dysfunction in a number of models of 
neurodegenerative disease and acute-subacute 
neurological insults, such as trauma and ischemia. In 
most cases  however, it is unclear whether  these 
beneficia1 effects are due to the anti-inflammatory 
properties that inhibition of caspase 1 affords, or are due 
to an effect on apoptotic pathways. In cell culture 
models, caspase inhibition generally provides only 
transient protection, most likely because of caspase- 
independent damage to the mitochondria. It remains to 
be seen whether in the animal models caspase inhibition 
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